T1	CHEM 1 11	Cefazolina
#1	AnnotatorNotes T1	C0007546; cefazolin; Organic Chemical · Antibiotic
T2	CHEM 16 30	Ciprofloxacino
#2	AnnotatorNotes T2	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T3	PROC 37 62	profilaxis de infecciones
#3	AnnotatorNotes T3	C0877629; Infection prophylaxis; Therapeutic or Preventive Procedure
T4	DISO 91 109	sangrado digestivo
#4	AnnotatorNotes T4	C0017181; Gastrointestinal Hemorrhage; Pathologic Function
T5	ANAT 100 109	digestivo
#5	AnnotatorNotes T5	C0012240; Gastrointestinal system; Body System
T6	CHEM 146 156	Cefazolina
#6	AnnotatorNotes T6	C0007546; cefazolin; Organic Chemical · Antibiotic
T7	PROC 162 184	profilaxis antibiótica
#7	AnnotatorNotes T7	C0282638; Antibiotic Prophylaxis; Therapeutic or Preventive Procedure
T8	DISO 230 241	infecciones
#8	AnnotatorNotes T8	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T9	DISO 270 288	sangrado digestivo
#9	AnnotatorNotes T9	C0017181; Gastrointestinal Hemorrhage; Pathologic Function
T10	ANAT 279 288	digestivo
#10	AnnotatorNotes T10	C0012240; Gastrointestinal system; Body System
T11	CHEM 304 318	Ciprofloxacino
#11	AnnotatorNotes T11	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T12	CHEM 1769 1780	antibiótica
#12	AnnotatorNotes T12	C0003232; Antibiotics; Antibiotic
T13	DISO 432 450	sangrado digestivo
#13	AnnotatorNotes T13	C0017181; Gastrointestinal Hemorrhage; Pathologic Function
T14	ANAT 441 450	digestivo
#14	AnnotatorNotes T14	C0012240; Gastrointestinal system; Body System
T15	PROC 456 466	ingresaron
#15	AnnotatorNotes T15	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T16	DISO 595 604	infección
#16	AnnotatorNotes T16	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T17	PROC 620 627	ingreso
#17	AnnotatorNotes T17	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T18	PROC 655 678	tratamiento antibiótico
#18	AnnotatorNotes T18	C0199779; Administration of antibiotic; Therapeutic or Preventive Procedure | C0338237; Antibiotic therapy; Therapeutic or Preventive Procedure
T19	CHEM 730 744	Ciprofloxacino
#19	AnnotatorNotes T19	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T20	CHEM 769 779	Cefazolina
#20	AnnotatorNotes T20	C0007546; cefazolin; Organic Chemical · Antibiotic
T21	CHEM 875 885	Cefazolina
#21	AnnotatorNotes T21	C0007546; cefazolin; Organic Chemical · Antibiotic
T22	CHEM 906 920	Ciprofloxacino
#22	AnnotatorNotes T22	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T23	DISO 992 999	ascitis
#23	AnnotatorNotes T23	C0003962; Ascites; Disease or Syndrome
T24	DISO 1018 1029	infecciones
#24	AnnotatorNotes T24	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T25	DISO 1220 1227	ascitis
#25	AnnotatorNotes T25	C0003962; Ascites; Disease or Syndrome
T26	DISO 1229 1242	encefalopatía
#26	AnnotatorNotes T26	C0006111; Brain Diseases; Disease or Syndrome | C0085584; Encephalopathies; Disease or Syndrome
T27	CHEM 173 184	antibiótica
#27	AnnotatorNotes T27	C0003232; Antibiotics; Antibiotic
T28	PROC 1275 1277	TP
#28	AnnotatorNotes T28	C0033707; Prothrombin time assay; Laboratory Procedure
T29	CHEM 1303 1311	Albúmina
#29	AnnotatorNotes T29	C0001924; Albumins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T30	CHEM 1330 1340	Cefazolina
#30	AnnotatorNotes T30	C0007546; cefazolin; Organic Chemical · Antibiotic
T31	DISO 1356 1367	infecciones
#31	AnnotatorNotes T31	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T32	DISO 1395 1406	infecciones
#32	AnnotatorNotes T32	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T33	CHEM 1431 1445	Ciprofloxacino
#33	AnnotatorNotes T33	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T34	DISO 1544 1551	ascitis
#34	AnnotatorNotes T34	C0003962; Ascites; Disease or Syndrome [Positive entity, double negation context]
T35	DISO 1576 1587	infecciones
#35	AnnotatorNotes T35	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T36	CHEM 1603 1613	cefazolina
#36	AnnotatorNotes T36	C0007546; cefazolin; Organic Chemical · Antibiotic
T37	CHEM 1638 1652	Ciprofloxacino
#37	AnnotatorNotes T37	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T38	CHEM 1725 1735	cefazolina
#38	AnnotatorNotes T38	C0007546; cefazolin; Organic Chemical · Antibiotic
T39	CHEM 1738 1752	ciprofloxacino
#39	AnnotatorNotes T39	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T40	PROC 1758 1780	profilaxis antibiótica
#40	AnnotatorNotes T40	C0282638; Antibiotic Prophylaxis; Therapeutic or Preventive Procedure
T41	DISO 1805 1823	sangrado digestivo
#41	AnnotatorNotes T41	C0017181; Gastrointestinal Hemorrhage; Pathologic Function
T42	ANAT 1814 1823	digestivo
#42	AnnotatorNotes T42	C0012240; Gastrointestinal system; Body System
T43	DISO 51 62	infecciones
#43	AnnotatorNotes T43	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T44	DISO 76 86	cirróticos
#44	AnnotatorNotes T44	C1623038; Cirrhosis; Disease or Syndrome
T45	DISO 255 265	cirróticos
#45	AnnotatorNotes T45	C1623038; Cirrhosis; Disease or Syndrome
T46	PROC 342 369	Ensayo Clínico aleatorizado
#46	AnnotatorNotes T46	C0206034; Clinical Trials, Randomized; Research Activity
T47	DISO 397 407	cirróticos
#47	AnnotatorNotes T47	C1623038; Cirrhosis; Disease or Syndrome
T48	CHEM 667 678	antibiótico
#48	AnnotatorNotes T48	C0003232; Antibiotics; Antibiotic
T49	PROC 1262 1273	Bilirrubina
#49	AnnotatorNotes T49	C0863174; Blood bilirubin measurement; Laboratory Procedure
T50	DISO 1077 1087	resangrado
#50	AnnotatorNotes T50	C3665429; Recurrent hemorrhage; Pathologic Function
T51	PROC 1279 1289	Creatinina
#51	AnnotatorNotes T51	C0201975; Creatinine measurement; Laboratory Procedure
T52	PROC 1292 1311	niveles de Albúmina
#52	AnnotatorNotes T52	C3525688; Measurement of albumin in plasma; Laboratory Procedure (?)
T53	DISO 1510 1520	cirróticos
#53	AnnotatorNotes T53	C1623038; Cirrhosis; Disease or Syndrome
T54	DISO 1794 1804	cirróticos
#54	AnnotatorNotes T54	C1623038; Cirrhosis; Disease or Syndrome
T55	LIVB 66 75	pacientes
#55	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	LIVB 245 254	pacientes
#56	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 387 396	pacientes
#57	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Age 408 426	mayores de 18 años
T59	Date 473 487	Julio del 2008
T60	Date 490 504	julio del 2010
T61	Neg_cue 574 576	ni
T64	Neg_cue 634 636	no
T65	Duration 679 700	las últimas 2 semanas
T66	Dose 745 751	200 mg
T67	Frequency 752 755	bid
T68	Route 756 758	EV
#58	AnnotatorNotes T68	C1522726; Intravenous Route of Drug Administration; Functional Concept
T69	Dose 780 783	1 g
T70	Frequency 784 787	tid
T71	Route 788 790	EV
#59	AnnotatorNotes T71	C1522726; Intravenous Route of Drug Administration; Functional Concept
T72	Duration 794 800	7 dias
T73	LIVB 836 845	pacientes
#60	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T74	LIVB 850 859	pacientes
#61	AnnotatorNotes T74	C0030705; Patients; Patient or Disabled Group
T75	Age 946 960	66 +/- 10 años
T78	LIVB 1500 1509	pacientes
#62	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T81	LIVB 1784 1793	pacientes
#63	AnnotatorNotes T81	C0030705; Patients; Patient or Disabled Group
T86	LIVB 1036 1045	población
#64	AnnotatorNotes T86	C1257890; Population; Population Group
T84	LIVB 967 974	varones
#65	AnnotatorNotes T84	C0025266; Male population group; Population Group
T62	Neg_cue 1472 1482	se excluyó
T63	PROC 1205 1218	estadio Child
#66	AnnotatorNotes T63	C3854424; Child-Pugh-Turcotte score; Laboratory Procedure
T76	PROC 1521 1526	Child
#67	AnnotatorNotes T76	C3854424; Child-Pugh-Turcotte score; Laboratory Procedure
T77	Neg_cue 552 555	sin
T79	Observation 556 573	evidencia clínica
T80	CONC 1102 1112	mortalidad
#68	AnnotatorNotes T80	C0026565; Mortality Vital Statistics; Quantitative Concept
T82	Neg_cue 1127 1129	No
T83	CONC 1135 1146	diferencias
#69	AnnotatorNotes T83	C1705241; Delta (difference); Quantitative Concept
T85	Neg_cue 1244 1246	ni
T87	CONC 1247 1258	en promedio
#70	AnnotatorNotes T87	C1510992; Average; Quantitative Concept
T88	Result_or_Value 1527 1528	A
T89	Neg_cue 1684 1686	no
T90	CONC 1692 1703	diferencias
#71	AnnotatorNotes T90	C1705241; Delta (difference); Quantitative Concept
A2	Assertion T16 Negated
A1	Assertion T18 Negated
A4	Assertion T48 Negated
A5	Assertion T78 Negated
A6	Assertion T53 Negated
R1	Used_for Arg1:T2 Arg2:T3
R2	Used_for Arg1:T1 Arg2:T3
R3	Experiences Arg1:T55 Arg2:T3
R4	Experiences Arg1:T55 Arg2:T43
R6	Overlap Arg1:T44 Arg2:T4
R7	Location_of Arg1:T5 Arg2:T4
R8	Experiences Arg1:T55 Arg2:T44
R9	Experiences Arg1:T55 Arg2:T4
R5	Used_for Arg1:T6 Arg2:T7
R10	Experiences Arg1:T56 Arg2:T8
R11	Experiences Arg1:T56 Arg2:T45
R12	Overlap Arg1:T45 Arg2:T9
R13	Experiences Arg1:T56 Arg2:T9
R14	Used_for Arg1:T11 Arg2:T7
R15	Experiences Arg1:T56 Arg2:T7
R16	Experiences Arg1:T57 Arg2:T47
R17	Has_Age Arg1:T57 Arg2:T58
R18	Experiences Arg1:T57 Arg2:T13
R19	Overlap Arg1:T47 Arg2:T13
R20	Location_of Arg1:T14 Arg2:T13
R21	Experiences Arg1:T57 Arg2:T15
R22	After Arg1:T15 Arg2:T59
R23	Before Arg1:T15 Arg2:T60
R24	Negation Arg1:T61 Arg2:T16
A3	Assertion T79 Negated
R25	Negation Arg1:T77 Arg2:T79
R26	Overlap Arg1:T16 Arg2:T17
R27	Overlap Arg1:T79 Arg2:T17
R28	Negation Arg1:T64 Arg2:T18
R29	Before Arg1:T18 Arg2:T17
R30	Used_for Arg1:T48 Arg2:T18
R31	Has_Duration_or_Interval Arg1:T18 Arg2:T65
R32	Has_Dose_or_Strength Arg1:T19 Arg2:T66
R33	Has_Frequency Arg1:T19 Arg2:T67
R34	Has_Route_or_Mode Arg1:T19 Arg2:T68
R35	Has_Dose_or_Strength Arg1:T20 Arg2:T69
R36	Has_Frequency Arg1:T20 Arg2:T70
R37	Has_Route_or_Mode Arg1:T20 Arg2:T71
R38	Has_Duration_or_Interval Arg1:T20 Arg2:T72
R39	Experiences Arg1:T74 Arg2:T21
R40	Experiences Arg1:T74 Arg2:T22
R42	Experiences Arg1:T86 Arg2:T24
R43	Experiences Arg1:T86 Arg2:T23
R44	Has_Age Arg1:T86 Arg2:T75
A7	Assertion T83 Negated
R41	Negation Arg1:T82 Arg2:T83
A8	Assertion T87 Negated
R45	Negation Arg1:T85 Arg2:T87
R46	Negation Arg1:T62 Arg2:T78
R47	Experiences Arg1:T78 Arg2:T53
R48	Experiences Arg1:T78 Arg2:T76
R49	Has_Result_or_Value Arg1:T76 Arg2:T88
R50	Experiences Arg1:T78 Arg2:T34
R51	Experiences Arg1:T78 Arg2:T35
R52	Experiences Arg1:T78 Arg2:T36
R53	Experiences Arg1:T78 Arg2:T37
A9	Assertion T90 Negated
R54	Negation Arg1:T89 Arg2:T90
R55	Used_for Arg1:T39 Arg2:T40
R56	Used_for Arg1:T38 Arg2:T40
R57	Experiences Arg1:T81 Arg2:T40
R58	Experiences Arg1:T81 Arg2:T54
R59	Experiences Arg1:T81 Arg2:T41
R60	Location_of Arg1:T42 Arg2:T41
R61	Overlap Arg1:T54 Arg2:T41
R62	Location_of Arg1:T10 Arg2:T9	
R64	Experiences Arg1:T57 Arg2:T16	
R63	Experiences Arg1:T57 Arg2:T18	
R65	Experiences Arg1:T73 Arg2:T21	
R66	Experiences Arg1:T73 Arg2:T22	
R67	Experiences Arg1:T56 Arg2:T11	
R68	Experiences Arg1:T57 Arg2:T17	
R69	Negation Arg1:T64 Arg2:T48	
R70	Has_Duration_or_Interval Arg1:T19 Arg2:T72	
R71	Negation Arg1:T62 Arg2:T53	
T91	Quantifier_or_Qualifier 1704 1718	significativas
A10	Assertion T91 Negated
#72	AnnotatorNotes T91	C0237881; Statistical Significance; Quantitative Concept
R75	Has_Quantifier_or_Qualifier Arg1:T90 Arg2:T91	
R76	Negation Arg1:T89 Arg2:T91	
R72	Before Arg1:T3 Arg2:T43	
R73	Before Arg1:T7 Arg2:T8	
T92	Quantifier_or_Qualifier 1147 1161	significativas
A11	Assertion T92 Negated
#73	AnnotatorNotes T92	C0750502; Significant; Idea or Concept
R74	Has_Quantifier_or_Qualifier Arg1:T83 Arg2:T92	
R77	Negation Arg1:T82 Arg2:T92	
#74	AnnotatorNotes T79	C5554846; Clinical Evidence; Finding
A12	Experiencer T55 Patient
A13	Experiencer T56 Patient
A14	Experiencer T57 Patient
A15	Experiencer T73 Patient
A16	Experiencer T74 Patient
A17	Experiencer T84 Patient
A18	Experiencer T86 Patient
A19	Experiencer T78 Patient
A20	Experiencer T81 Patient
